We included observational cohort studies (prospective or retrospective) and randomized controlled trials (RCTs) that evaluated the effects of SGLT2 inhibitors on cardiovascular outcomes in adult cancer patients (≥18 years) with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.